

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Davis, et al.

Serial No.: Not Yet Known

Group: Not Yet Assigned

Filing Date: Filed Herewith

Examiner: Not Yet Assigned

Title: TIE-2 LIGANDS, METHODS OF MAKING AND USES THEREOF

June 25, 2003

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
US Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

- [X]** (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

Or

Express Mail Label No. ET712521997US

[] (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

[] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

[] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

[] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

[] (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

[] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

[] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

[] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).


REQUEST FOR TRANSFER OF REFERENCE COPIES

- [X] Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN 09/442,717 filed November 18, 1999 be transferred to the subject application for consideration by the Examiner

Fees

The fee required for the filing of this Information Disclosure Statement is estimated to be \$ _____. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

Respectfully submitted



Linda O. Palladino

Reg. No. 45,636

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No.: REG 330G1Z
 USSN: Not Yet Known
 Applicant: Davis, et al.
 Date Filed: November 18, 1999
 For: TIE-2 LIGANDS, METHODS OF MAKING AND USES THEREOF
 Examiner: Not Yet Known
 Group Art Unit: Not Yet Known

June 25, 2003

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	5,643,755	7/1/97	Davis, et al.		10/7/94
_____	5,521,073	5/28/96	Davis, et al.		10/27/94
_____	5,650,490	7/22/97	Davis, et al.		1/17/95
_____	5,814,464	9/29/98	Davis, et al.		4/6/95
_____	5,879,672	3/9/99	Davis, et al.		12/2/94
_____	5,332,671	7/26/94	Ferrara, et al.		8/4/89

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation</u>	
					<u>Yes</u>	<u>No</u>
_____	WO95/26364	10/2/95	PCT			
_____	0550296A2	7/7/93	Europe			

Att. Dkt. No. REG 330G1Z
USSN Not Yet Known
File Date: Filed Herewith
Form PTO-1449

OTHER DOCUMENTS
(Including Author, Title, Date, Pertinent Pages, etc.)

Examiner
Initials

_____	Banai, et al., Circulation, 1994, 89:2183-2189
_____	Unger, et al., Am. J. Physiol., 1994, 266:H1588-H1595
_____	Lazarous, et al., Circulation, 1995, 91:145-153
_____	Burrows, F. and Thorpe, P., PNAS (USA) 1993, 90:8996-9000

EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

Linda O. Palladino

Linda O. Palladino
Reg. No. 45,636
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
914-345-7400